Metagenomi Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	47.26	44.76	17.2	0.24
Revenue Growth (YoY)	109.93%	160.21%	6978.19%	-
Cost of Revenue	105.71	94.4	43.14	14.48
Gross Profit	-58.45	-49.65	-25.94	-14.24
Selling, General & Admin	31.13	28.85	18.7	9.71
Operating Expenses	31.13	28.85	18.7	9.71
Operating Income	-89.59	-78.49	-44.64	-23.95
Interest Expense	-	-	-0.1	-0.3
Interest & Investment Income	15.4	15.47	3.42	0.04
Other Non Operating Income (Expenses)	-0.12	-0.07	0.2	0
EBT Excluding Unusual Items	-74.31	-63.1	-41.12	-24.2
Gain (Loss) on Sale of Investments	2.87	2.87	0.09	2.76
Pretax Income	-71.44	-60.23	-41.02	-21.44
Income Tax Expense	5.83	8.03	2.57	-
Net Income	-77.27	-68.26	-43.59	-21.44
Net Income to Common	-77.27	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	8	3	3	6
Shares Outstanding (Diluted)	8	3	3	6
Shares Change (YoY)	183.14%	0.15%	-40.27%	-
EPS (Basic)	-9.86	-20.05	-12.82	-3.77
EPS (Diluted)	-9.86	-20.05	-12.82	-3.77
Free Cash Flow	-108.33	-101.22	15.75	21.35
Free Cash Flow Per Share	-13.82	-29.73	4.63	3.75
Gross Margin	-123.69%	-110.93%	-150.81%	-
Operating Margin	-189.57%	-175.38%	-259.53%	-9854.73%
Profit Margin	-163.51%	-152.50%	-253.45%	-
Free Cash Flow Margin	-229.22%	-226.17%	91.55%	8787.65%
EBITDA	-84.95	-74.29	-42.91	-23.56
EBITDA Margin	-179.75%	-165.98%	-249.46%	-
D&A For EBITDA	4.64	4.21	1.73	0.39
EBIT	-89.59	-78.49	-44.64	-23.95
EBIT Margin	-189.57%	-175.38%	-259.53%	-

Source: S&P Capital IQ. Standard template.